Accrued taxes of $62.5 million and $32.2 million have been included in other current liabilities within the consolidated balance sheets as of December 29, 2017, and December 30, 2016, respectively.
At December 29, 2017, the Company had $13.6 million for capital equipment that was accrued to other long-term liabilities, and $8.6 million for capital equipment that was accrued to accounts payable.
On November 15, 2017, the Company agreed to potentially issue not more than 1% of our common stock to an unaffiliated third party as a contingent consideration for its role under a multi-year collaboration agreement, upon the achievement of certain product sales milestones.
The shares have been valued utilizing a Monte Carlo valuation model and could be issued after mid-2020.
The repurchase program may be suspended or discontinued at any time.
In connection with certain facility leases, the Company has indemnified its lessors for certain claims arising from the facility or the lease.
The Company currently expects to fund the repurchase program using the Company’s working capital.We generated net revenue of $1,051.9 million for the three months ended December 29, 2017, an increase of $137.6 million or 15%, as compared with $914.3 million for the corresponding period in fiscal year 2017.
Our cost of goods sold consists primarily of purchased materials, labor and overhead (including depreciation and share-based compensation expense) associated with product manufacturing.
Our cost of goods sold consists primarily of purchased materials, labor and overhead (including depreciation and share-based compensation expense) associated with product manufacturing.
Our contractual obligations disclosure in the 2017 10-K has not materially changed since we filed that report, except for the $257.8 million deemed repatriation tax on foreign earnings, which is payable over the next eight years, $20.6 million per year for each of the next five years, followed by payments of $38.7 million, $51.6 million and $64.5 million in years six through eight, respectively.
Cash and cash equivalent balances were $1,681.5 million as of December 29, 2017, representing an increase of $64.7 million from September 29, 2017.
Though the timing is not certain, the Company does not expect achievement of the product sale milestones to occur any time prior to mid-2020.2016-16, Income taxes (Topic 740), Intra-entity transfers of an asset other than inventory (“ASU 2016-16”).
Our assessment will be completed during fiscal year 2018 at which time the method of adoption will be selected.
We will adopt this guidance during the first quarter of fiscal year 2019.Other Information.
On November 15, 2017, we agreed to potentially issue not more than 1% of our common stock to an unaffiliated third party as contingent consideration for its role under a multi-year collaboration agreement.